Please Wait.....
Report
Joint Pain Injections Market By Injection Type (Interleukin Inhibitors, Hyaluronic Acid Injections, Others), By Joint Type (Knee and Ankle, Hip Joint, Shoulder and Elbow, Facet Joints of the Spine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-11-01 I 310 Pages I Allied Market Research
The global joint pain injections market was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Joint pain injections refer to the non-surgical procedures that involves application of the medication directly to damage joint tissue. Joint pain is defined as the discomfort caused into the joints which is associated with the various reasons including the arthritis and its different kinds, the previous injuries to a joint, overuse of the muscle, depression, anxiety, stress, and obesity. Furthermore, interleukin inhibitors are one of the most common types of therapeutic injections that include an anesthetic agent combined with a corticosteroid to relieve joint pain and inflammation.
According to the Arthritis Foundation, as of the numbers generated in 2022 there are about 60 million adults who have been diagnosed with arthritis and 1 in 4 adults have one of these types of arthritis. This rise in incidence of arthritis among all age groups owing to a sedentary lifestyle, rise in obesity, injuries due to physical activities and stress, will lead to the sales of the joint pain injection on a large scale.
Furthermore, the joint pain injections market is anticipated to grow by the introduction of numerous cutting-edge treatment technologies by the pharmaceutical companies, an increase in the demand for accurate treatment options by the patients, and the availability of high income in the developed economies.
Arthritis Foundation also states that, the inflammatory and rheumatic diseases that develops in children under the age of 16 is known to be juvenile arthritis, which affects nearly 300,000 kids and teens in the U.S. However, the government of Australia has published 'The National Strategic Action Plan for Arthritis' that aims to guide national efforts to address the burden of arthritis. Thus, such more initiatives and funding provided by the government will boost the growth of the market.
In addition, the rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the key factors for the expansion of the joint pain injections market. For instance, the U.S. FDA approval for the second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis that can be administered with a single injection four times a year.
However, the market is expected to be significantly constrained in the near future by factors such as lack of awareness about these injections in developing nations, their expensive price, and lack of reimbursement policies that effects the adoption of the products in the emerging countries. However, the key market players are developing more efficient treatment options which includes the single injection therapy and plasma matrix therapy, which will provide lucrative opportunities during the forecast period.
The joint pain injections market is segmented on the basis of injection type, by joint type, by distribution channel and region. By injection type, it is divided into interleukin inhibitors, hyaluronic acid injections and others. On the basis of joint type, the market is segmented into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. According to the distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies and online providers. Further, the hospital pharmacies segment is divided into public hospital pharmacies and private hospital pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Injection Type
- Interleukin Inhibitors
- Hyaluronic Acid Injections
- Others
By Joint Type
- Knee and Ankle
- Hip Joint
- Shoulder and Elbow
- Facet Joints of the Spine
- Others
By Distribution Channel
- Hospital Pharmacies
- Type
- Public Hospital Pharmacies
- Private Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Abbvie Inc
- Anika Therapeutics
- Bioventus
- Eli Lilly and Company
- Ferring Pharmaceuticals Inc.
- PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceuticals
- Zimmer Biomet
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Interleukin Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Hyaluronic Acid Injections
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Knee and Ankle
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hip Joint
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Shoulder and Elbow
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Facet Joints of the Spine
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Others
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Hospital Pharmacies Joint Pain Injections Market by Type
6.2.4.1 Public Hospital Pharmacies Market size and forecast, by region
6.2.4.2 Private Hospital Pharmacies Market size and forecast, by region
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: JOINT PAIN INJECTIONS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Injection Type
7.2.3 North America Market size and forecast, by Joint Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.4.1 North America Hospital Pharmacies Joint Pain Injections Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Injection Type
7.2.5.1.2 Market size and forecast, by Joint Type
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Injection Type
7.2.5.2.2 Market size and forecast, by Joint Type
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Injection Type
7.2.5.3.2 Market size and forecast, by Joint Type
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Injection Type
7.3.3 Europe Market size and forecast, by Joint Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.4.1 Europe Hospital Pharmacies Joint Pain Injections Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Injection Type
7.3.5.1.2 Market size and forecast, by Joint Type
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Injection Type
7.3.5.2.2 Market size and forecast, by Joint Type
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Injection Type
7.3.5.3.2 Market size and forecast, by Joint Type
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Injection Type
7.3.5.4.2 Market size and forecast, by Joint Type
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Injection Type
7.3.5.5.2 Market size and forecast, by Joint Type
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Injection Type
7.3.5.6.2 Market size and forecast, by Joint Type
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Injection Type
7.4.3 Asia-Pacific Market size and forecast, by Joint Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.4.1 Asia-Pacific Hospital Pharmacies Joint Pain Injections Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Injection Type
7.4.5.1.2 Market size and forecast, by Joint Type
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Injection Type
7.4.5.2.2 Market size and forecast, by Joint Type
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Injection Type
7.4.5.3.2 Market size and forecast, by Joint Type
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Injection Type
7.4.5.4.2 Market size and forecast, by Joint Type
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Injection Type
7.4.5.5.2 Market size and forecast, by Joint Type
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Injection Type
7.4.5.6.2 Market size and forecast, by Joint Type
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Injection Type
7.5.3 LAMEA Market size and forecast, by Joint Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.4.1 LAMEA Hospital Pharmacies Joint Pain Injections Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Injection Type
7.5.5.1.2 Market size and forecast, by Joint Type
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Injection Type
7.5.5.2.2 Market size and forecast, by Joint Type
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Injection Type
7.5.5.3.2 Market size and forecast, by Joint Type
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Injection Type
7.5.5.4.2 Market size and forecast, by Joint Type
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Anika Therapeutics
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bioventus
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Ferring Pharmaceuticals Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sanofi S.A.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceuticals
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Zimmer Biomet
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 2. JOINT PAIN INJECTIONS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. JOINT PAIN INJECTIONS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. JOINT PAIN INJECTIONS MARKET, FOR HYALURONIC ACID INJECTIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. JOINT PAIN INJECTIONS MARKET FOR HYALURONIC ACID INJECTIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 9. JOINT PAIN INJECTIONS MARKET, FOR KNEE AND ANKLE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. JOINT PAIN INJECTIONS MARKET FOR KNEE AND ANKLE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. JOINT PAIN INJECTIONS MARKET, FOR HIP JOINT, BY REGION, 2021-2031 ($MILLION)
TABLE 12. JOINT PAIN INJECTIONS MARKET FOR HIP JOINT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. JOINT PAIN INJECTIONS MARKET, FOR SHOULDER AND ELBOW, BY REGION, 2021-2031 ($MILLION)
TABLE 14. JOINT PAIN INJECTIONS MARKET FOR SHOULDER AND ELBOW, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. JOINT PAIN INJECTIONS MARKET, FOR FACET JOINTS OF THE SPINE, BY REGION, 2021-2031 ($MILLION)
TABLE 16. JOINT PAIN INJECTIONS MARKET FOR FACET JOINTS OF THE SPINE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. JOINT PAIN INJECTIONS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. JOINT PAIN INJECTIONS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. JOINT PAIN INJECTIONS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 21. JOINT PAIN INJECTIONS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. GLOBAL HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 23. JOINT PAIN INJECTIONS MARKET, FOR PUBLIC HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. JOINT PAIN INJECTIONS MARKET, FOR PRIVATE HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 25. JOINT PAIN INJECTIONS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 26. JOINT PAIN INJECTIONS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. JOINT PAIN INJECTIONS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. JOINT PAIN INJECTIONS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. JOINT PAIN INJECTIONS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 35. U.S. JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 36. U.S. JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 37. U.S. JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. CANADA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 39. CANADA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 40. CANADA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. MEXICO JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 42. MEXICO JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 43. MEXICO JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 46. EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. EUROPE HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 49. GERMANY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 50. GERMANY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 51. GERMANY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. FRANCE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 53. FRANCE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. UK JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 56. UK JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 57. UK JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. ITALY JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 59. ITALY JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 60. ITALY JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. SPAIN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 62. SPAIN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 63. SPAIN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 66. REST OF EUROPE JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 72. JAPAN JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 73. JAPAN JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 74. JAPAN JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. CHINA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 76. CHINA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 77. CHINA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. INDIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 82. INDIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 83. INDIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 86. SOUTH KOREA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 91. LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 92. LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 93. LAMEA HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. LAMEA JOINT PAIN INJECTIONS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 95. BRAZIL JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 96. BRAZIL JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 97. BRAZIL JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 100. SAUDI ARABIA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 103. SOUTH AFRICA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY INJECTION TYPE, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE, 2021-2031 ($MILLION)
TABLE 106. REST OF LAMEA JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
TABLE 108.ABBVIE INC: OPERATING SEGMENTS
TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 110.ABBVIE INC: NET SALES,
TABLE 111.ABBVIE INC: KEY STRATERGIES
TABLE 112.ANIKA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 113.ANIKA THERAPEUTICS: OPERATING SEGMENTS
TABLE 114.ANIKA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 115.ANIKA THERAPEUTICS: NET SALES,
TABLE 116.ANIKA THERAPEUTICS: KEY STRATERGIES
TABLE 117.BIOVENTUS: COMPANY SNAPSHOT
TABLE 118.BIOVENTUS: OPERATING SEGMENTS
TABLE 119.BIOVENTUS: PRODUCT PORTFOLIO
TABLE 120.BIOVENTUS: NET SALES,
TABLE 121.BIOVENTUS: KEY STRATERGIES
TABLE 122.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 123.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 124.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 125.ELI LILLY AND COMPANY: NET SALES,
TABLE 126.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 127.FERRING PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 128.FERRING PHARMACEUTICALS INC.: OPERATING SEGMENTS
TABLE 129.FERRING PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 130.FERRING PHARMACEUTICALS INC.: NET SALES,
TABLE 131.FERRING PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 132.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): COMPANY SNAPSHOT
TABLE 133.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): OPERATING SEGMENTS
TABLE 134.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): PRODUCT PORTFOLIO
TABLE 135.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): NET SALES,
TABLE 136.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.): KEY STRATERGIES
TABLE 137.PFIZER INC.: COMPANY SNAPSHOT
TABLE 138.PFIZER INC.: OPERATING SEGMENTS
TABLE 139.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 140.PFIZER INC.: NET SALES,
TABLE 141.PFIZER INC.: KEY STRATERGIES
TABLE 142.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 143.SANOFI S.A.: OPERATING SEGMENTS
TABLE 144.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 145.SANOFI S.A.: NET SALES,
TABLE 146.SANOFI S.A.: KEY STRATERGIES
TABLE 147.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 148.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 149.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 150.TEVA PHARMACEUTICALS: NET SALES,
TABLE 151.TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 152.ZIMMER BIOMET: COMPANY SNAPSHOT
TABLE 153.ZIMMER BIOMET: OPERATING SEGMENTS
TABLE 154.ZIMMER BIOMET: PRODUCT PORTFOLIO
TABLE 155.ZIMMER BIOMET: NET SALES,
TABLE 156.ZIMMER BIOMET: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.JOINT PAIN INJECTIONS MARKET SEGMENTATION
FIGURE 2.JOINT PAIN INJECTIONS MARKET,2021-2031
FIGURE 3.JOINT PAIN INJECTIONS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.JOINT PAIN INJECTIONS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PATENT ANALYSIS BY COMPANY
FIGURE 13.PATENT ANALYSIS BY COUNTRY
FIGURE 14.JOINT PAIN INJECTIONS MARKET,BY INJECTION TYPE,2021(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INTERLEUKIN INHIBITORS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HYALURONIC ACID INJECTIONS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 18.JOINT PAIN INJECTIONS MARKET,BY JOINT TYPE,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF KNEE AND ANKLE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HIP JOINT JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SHOULDER AND ELBOW JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF FACET JOINTS OF THE SPINE JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 24.JOINT PAIN INJECTIONS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS JOINT PAIN INJECTIONS MARKET,2021-2031(%)
FIGURE 28.JOINT PAIN INJECTIONS MARKET BY REGION,2021
FIGURE 29.U.S. JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 30.CANADA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 31.MEXICO JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 32.GERMANY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 33.FRANCE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 34.UK JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 35.ITALY JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 36.SPAIN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 37.REST OF EUROPE JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 38.JAPAN JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 39.CHINA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 40.AUSTRALIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 41.INDIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 42.SOUTH KOREA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 43.REST OF ASIA-PACIFIC JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 44.BRAZIL JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 45.SAUDI ARABIA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 46.SOUTH AFRICA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 47.REST OF LAMEA JOINT PAIN INJECTIONS MARKET,2021-2031($MILLION)
FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 52.COMPETITIVE DASHBOARD
FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 54.ABBVIE INC.: NET SALES ,($MILLION)
FIGURE 55.ANIKA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 56.BIOVENTUS.: NET SALES ,($MILLION)
FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 58.FERRING PHARMACEUTICALS INC..: NET SALES ,($MILLION)
FIGURE 59.PACIRA BIOSCIENCES (FLEXION THERAPEUTICS, INC.).: NET SALES ,($MILLION)
FIGURE 60.PFIZER INC..: NET SALES ,($MILLION)
FIGURE 61.SANOFI S.A..: NET SALES ,($MILLION)
FIGURE 62.TEVA PHARMACEUTICALS.: NET SALES ,($MILLION)
FIGURE 63.ZIMMER BIOMET.: NET SALES ,($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security